These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209 [TBL] [Abstract][Full Text] [Related]
3. CD205 Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883 [TBL] [Abstract][Full Text] [Related]
4. Distinct Role of CD11b Wu SY; Chiang CS Cells; 2019 Dec; 9(1):. PubMed ID: 31878276 [TBL] [Abstract][Full Text] [Related]
5. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury. Zhang C; Wang S; Li J; Zhang W; Zheng L; Yang C; Zhu T; Rong R Cell Death Dis; 2017 Mar; 8(3):e2695. PubMed ID: 28333137 [TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624 [TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Ly6G Heim CE; West SC; Ali H; Kielian T Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249747 [TBL] [Abstract][Full Text] [Related]
8. CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice. Foks AC; Van Puijvelde GH; Wolbert J; Kröner MJ; Frodermann V; Van Der Heijden T; Van Santbrink PJ; Boon L; Bot I; Kuiper J Cardiovasc Res; 2016 Aug; 111(3):252-61. PubMed ID: 27234908 [TBL] [Abstract][Full Text] [Related]
9. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002 [TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. Shime H; Maruyama A; Yoshida S; Takeda Y; Matsumoto M; Seya T Oncoimmunology; 2017; 7(1):e1373231. PubMed ID: 29296526 [TBL] [Abstract][Full Text] [Related]
12. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway. Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418 [TBL] [Abstract][Full Text] [Related]
13. Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions. Spallanzani RG; Dalotto-Moreno T; Raffo Iraolagoitia XL; Ziblat A; Domaica CI; Avila DE; Rossi LE; Fuertes MB; Battistone MA; Rabinovich GA; Salatino M; Zwirner NW Cancer Immunol Immunother; 2013 Dec; 62(12):1781-95. PubMed ID: 24114144 [TBL] [Abstract][Full Text] [Related]
14. CD33 Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700 [TBL] [Abstract][Full Text] [Related]
15. Visualization and quantification of Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525 [TBL] [Abstract][Full Text] [Related]
16. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice. Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Liu D; You M; Xu Y; Li F; Zhang D; Li X; Hou Y Int Immunopharmacol; 2016 Oct; 39():265-272. PubMed ID: 27497194 [TBL] [Abstract][Full Text] [Related]
18. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Kodumudi KN; Woan K; Gilvary DL; Sahakian E; Wei S; Djeu JY Clin Cancer Res; 2010 Sep; 16(18):4583-94. PubMed ID: 20702612 [TBL] [Abstract][Full Text] [Related]
19. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Lee M; Park CS; Lee YR; Im SA; Song S; Lee CK Arch Pharm Res; 2014; 37(9):1234-40. PubMed ID: 24748512 [TBL] [Abstract][Full Text] [Related]
20. mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors. Wu T; Zhao Y; Wang H; Li Y; Shao L; Wang R; Lu J; Yang Z; Wang J; Zhao Y Sci Rep; 2016 Feb; 6():20250. PubMed ID: 26833095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]